Izvorni znanstveni članak
EFFICACY AND SAFETY OF NPH (NEUTRAL PROTAMINE HAGEDORN) INSULIN COMPARED WITH INSULIN GLARGINE IN PATIENTS WITH TYPE 2 DIABETES
PETRA KLANAC
; Medicinski fakultet Zagreb, Sveučilište u Zagrebu, Zagreb, Hrvatska
MARKO KAŠTELAN
; Medicinski fakultet Zagreb, Sveučilište u Zagrebu, Zagreb, Hrvatska
IVANA KRALJEVIĆ
; Medicinski fakultet Zagreb, Sveučilište u Zagrebu, Zagreb, Hrvatska; Zavod za endokrinologiju, Klinički bolnički centar Zagreb, Zagreb, Hrvatska
TOMISLAV BULUM
; Medicinski fakultet Zagreb, Sveučilište u Zagrebu, Zagreb, Hrvatska; Zavod za dijabetes, endokrinologiju i metaboličke bolesti, Klinička bolnica Merkur, Zagreb, Hrvatska
ANELA NOVAK
; Medicinski Fakultet Split, Sveučilište u Splitu, Zavod za endokrinologiju, Klinički bolnički centar Split, Split, Hrvatska
ANNEMARIE BALAŠKO
; Zavod za endokrinologiju, Klinički bolnički centar Zagreb, Zagreb, Hrvatska
MAJA JURIĆ SAMARDŽIĆ
; Odjel za internu medicinu, Opća bolnica Slavonski Brod, Slavonski Brod, Hrvatska
KARIN ZIBAR TOMŠIĆ
; Zavod za endokrinologiju, Klinički bolnički centar Zagreb, Zagreb, Hrvatska
MAJA BARETIĆ
; Medicinski fakultet Zagreb, Sveučilište u Zagrebu, Zagreb, Hrvatska; Zavod za endokrinologiju, Klinički bolnički centar Zagreb, Zagreb, Hrvatska
MAJA MIKOLAJ KIRIĆ
; Odjel za internu medicinu, Županijska bolnica Čakovec, Čakovec, Hrvatska
TANJA MILIČEVIĆ MILARDOVIĆ
; Medicinski Fakultet Split, Sveučilište u Splitu, Zavod za endokrinologiju, Klinički bolnički centar Split, Split, Hrvatska
HRVOJE POPOVAC
; Zavod za endokrinologiju, Klinički bolnički centar Zagreb, Zagreb, Hrvatska
TANJA ŠKORIĆ POLOVINA
; Zavod za endokrinologiju, Klinički bolnički centar Zagreb, Zagreb, Hrvatska
MARIJA TRIPOLSKI
; Zavod za endokrinologiju, Klinika za unutarnje bolesti, Klinički bolnički centar Osijek, Osijek, Hrvatska
TATJANA BAČUN
; Zavod za endokrinologiju, Klinika za unutarnje bolesti, Klinički bolnički centar Osijek, Osijek, Hrvatska; Medicinski fakultet Osijek, Sveučilište Josipa Jurja Strossmayera u Osijeku, Osijek, Hrvatska
MIRSALA SOLAK
; Zavod za endokrinologiju, Klinički bolnički centar Zagreb, Zagreb, Hrvatska
SIDBELA ZUKANOVIĆ
; Odjel za internu medicinu, Opća bolnica Slavonski Brod, Slavonski Brod, Hrvatska
TINA DUŠEK
; Medicinski fakultet Zagreb, Sveučilište u Zagrebu, Zagreb, Hrvatska; Zavod za endokrinologiju, Klinički bolnički centar Zagreb, Zagreb, Hrvatska
DARKO KAŠTELAN
; Medicinski fakultet Zagreb, Sveučilište u Zagrebu, Zagreb, Hrvatska; Zavod za endokrinologiju, Klinički bolnički centar Zagreb, Zagreb, Hrvatska
*
* Dopisni autor.
Sažetak
Background: Insulin therapy is often required for achieving adequate glycemic control in patients with type 2 diabetes mellitus (DM2). For that purpose, the insulin analogue glargine is most commonly used in clinical practice, while only a minority of patients
are given the cheaper NPH (Neutral Protamine Hagedorn) human insulin. Methods: In this observational multicenter study we
compared the efficacy and safety of insulin glargine and human NPH insulin. During a six-month follow-up period two groups of
patients with DM2 were observed. One group was administered NPH insulin while insulin glargine was administered in the other
group (53 and 48 participants, respectively). Results: After six months, both patient groups achieved the same hemoglobin A1c
(HbA1c) level (7.5 ± 1 %). In both groups a small statistically nonsignificant increase in body weight was observed. The daily dose of insulin (measured in international units, IU) was significantly higher in the glargine group than in the NPH insulin group (22.4 ± 8.5 IU vs 18.6 ± 7.8 IU). The incidence of hypoglycemia was similar in both groups. Conclusion: Our study revealed no significant difference in the risk of hypoglycemia or in efficacy between insulin glargine and NPH insulin in patients with DM2. Accordingly, our results suggest that human NPH insulin may be an effective and safe treatment for the majority of patients with DM2.
Ključne riječi
type 2 diabetes mellitus; insulin glargine; NPH insulin; hypoglycemia, long-acting insulin
Hrčak ID:
331219
URI
Datum izdavanja:
16.5.2025.
Posjeta: 318 *